Freddie B, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https://doi.org/10.3322/caac.21834

Article  Google Scholar 

Tan ZB, Zhang J. Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus. Eur Rev Med Pharmacol Sci. 2023;27(17):8119–8134

PubMed  Google Scholar 

Masatoshi K, et al. Report of the 20th nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res. 2019. https://doi.org/10.1111/hepr.13438

Article  Google Scholar 

Nakazawa T, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol. 2014;14: 84

PubMed  PubMed Central  Google Scholar 

Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173

CAS  PubMed  Google Scholar 

Finn RS, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905

CAS  PubMed  Google Scholar 

Li QJ, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2022;40(2):150–160

CAS  PubMed  Google Scholar 

Finn RS, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–2970

PubMed  PubMed Central  Google Scholar 

Qin S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. 2023;402(10408):1133–1146

CAS  PubMed  Google Scholar 

Finn RS, et al. LBA34 primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022. https://doi.org/10.1016/j.annonc.2022.08.031

Article  Google Scholar 

Fu Y, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and PD1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023;58(4):413–424

CAS  PubMed  Google Scholar 

Shuntaro O, Shinpei S, Toshihiro K. Current status of hepatic arterial infusion chemotherapy. Liver Cancer. 2015. https://doi.org/10.1159/000367746

Article  Google Scholar 

Chang X, et al. HAIC combined with lenvatinib plus PD-1 versus lenvatinib plus PD-1 in patients with high-risk advanced HCC: a real-world study. BMC Cancer. 2024;24(1):480

CAS  PubMed  PubMed Central  Google Scholar 

Xu C, et al. Hepatic arterial infusion chemotherapy combined with lenvatinib plus humanized programmed death receptor-1 in patients with high-risk advanced hepatocellular carcinoma: a real-world study. J Hepatocell Carcinoma. 2023. https://doi.org/10.2147/JHC.S418387

Article  PubMed  PubMed Central  Google Scholar 

Yidan L, et al. Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib plus PD-1 inhibitors in hepatocellular carcinoma patients with tumor thrombosis in the inferior vena cava and/or right atrium. Acad Radiol. 2024. https://doi.org/10.1016/j.acra.2024.08.058

Article  Google Scholar 

Wentao B, Yan C. Lenvatinib resistance mechanism and potential ways to conquer. Front Pharmacol. 2023. https://doi.org/10.3389/fphar.2023.1153991

Article  Google Scholar 

Yizhen F, et al. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol. 2023. https://doi.org/10.1007/s00535-023-01976-x

Article  Google Scholar 

Renguo G, et al. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors. Int J Surg. 2024. https://doi.org/10.1097/JS9.0000000000001378

Article  Google Scholar 

Chuma M, et al. Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: a multicenter analysis. Hepatol Res. 2021;51(2):201–215

CAS  PubMed  Google Scholar 

Sun X, et al. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer. 2022;22(1): 293

CAS  PubMed  PubMed Central  Google Scholar 

He M, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–960

PubMed  PubMed Central  Google Scholar 

Zheng K, et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis: a randomized trial. Radiology. 2022;303(2):455–464

PubMed  Google Scholar 

Rita G, et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension? J Vasc Interv Radiol. 2013. https://doi.org/10.1016/j.jvir.2012.12.013

Article  Google Scholar 

Qi-Jiong L, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol. 2021. https://doi.org/10.1200/JCO.21.00608

Article  Google Scholar 

Li SQ, et al. Transarterial chemoembolization plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: a multicenter retrospective study. J Hepatocell Carcinoma. 2023;10:1799–1811

CAS  PubMed  PubMed Central  Google Scholar 

Yu W, et al. Transarterial interventional therapy combined with tyrosine kinase inhibitors with or without anti-PD-1 antibodies as initial treatment for hepatocellular carcinoma with major portal vein tumor thrombosis: a single-center retrospective study. Cancer Immunol Immunother. 2023;72(11):3609–3619

CAS  PubMed  PubMed Central  Google Scholar 

Mingyue C, et al. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study. Int J Surg. 2024;110(12):7860–7870

Google Scholar 

Kaina C, et al. The impact of radiation dose and tumour burden on outcomes in hepatocellular carcinoma: 11-year experience in a 413-patient cohort treated with yttrium-90 resin microsphere radioembolisation. Liver Cancer. 2025. https://doi.org/10.1159/000541539

Article  Google Scholar 

Delia DA, et al. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2021. https://doi.org/10.1016/j.jhep.2021.11.013

Article  Google Scholar 

Alessandro G, et al. TRANS-TACE: prognostic role of the transient hypertransaminasemia after conventional chemoembolization for hepatocellular carcinoma. J Pers Med. 2021. https://doi.org/10.3390/jpm11101041

Article  Google Scholar